With an impact on 2% to 7% of pregnancies, preeclampsia is a major contributor to maternal and neonatal death. This study examines the potential advantages of vitamin E and C supplements for high-risk expectant women in order to mitigate the risk of preeclampsia.
Methods:
This double-arm randomized controlled trial comprised two groups: 588 primigravida women at 18-22 weeks gestation with aberrant uterine artery Doppler readings (84 of whom were identified as high-risk) and the preeclampsia history of fifty women or related conditions. Vitamins C and E, or a placebo, were given to one hundred volunteers at random. Doppler scans and levels of plasminogen activator inhibitors 1 and 2 were used to track their progress throughout the pregnancy (PAI-2).patient's preeclampsia history
Results:
Preeclamptic women exhibited significantly higher PAI-1 levels than normotensive women (165 ± 72.9 vs. 110.9 ± 37.7, P = 0.03), whereas PAI-2 levels were substantially lower (104 ± 33.8 vs. 180.7 ± 66.8, P = 0.018). The intervention group had a preeclampsia prevalence of 8%, opposite of what happened in the control group because they a prevalence of 24% (P = 0.123). The occurrence of gestational hypertension (18% vs. 12%, P = 0.713) and blood pressure values between the groups were not significantly different.
Conclusion:
Taking preeclampsia prevention vitamins C and E did not lower the likelihood of the condition in high-risk pregnant women.. In order to investigate the potential benefits or limitations of antioxidants in the prevention of preeclampsia, it is imperative to conduct larger, multicentre trials.